222 related articles for article (PubMed ID: 34301761)
1. Modeling High-Grade Serous Ovarian Carcinoma Using a Combination of
Teng K; Ford MJ; Harwalkar K; Li Y; Pacis AS; Farnell D; Yamanaka N; Wang YC; Badescu D; Ton Nu TN; Ragoussis J; Huntsman DG; Arseneau J; Yamanaka Y
Cancer Res; 2021 Oct; 81(20):5147-5160. PubMed ID: 34301761
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.
Walton JB; Farquharson M; Mason S; Port J; Kruspig B; Dowson S; Stevenson D; Murphy D; Matzuk M; Kim J; Coffelt S; Blyth K; McNeish IA
Sci Rep; 2017 Dec; 7(1):16827. PubMed ID: 29203787
[TBL] [Abstract][Full Text] [Related]
3. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
4. Reprogramming Mouse Oviduct Epithelial Cells Using In Vivo Electroporation and CRISPR/Cas9-Mediated Genetic Manipulation.
Ford MJ; Yamanaka Y
Methods Mol Biol; 2022; 2429():367-377. PubMed ID: 35507174
[TBL] [Abstract][Full Text] [Related]
5. High grade serous ovarian carcinomas originate in the fallopian tube.
Labidi-Galy SI; Papp E; Hallberg D; Niknafs N; Adleff V; Noe M; Bhattacharya R; Novak M; Jones S; Phallen J; Hruban CA; Hirsch MS; Lin DI; Schwartz L; Maire CL; Tille JC; Bowden M; Ayhan A; Wood LD; Scharpf RB; Kurman R; Wang TL; Shih IM; Karchin R; Drapkin R; Velculescu VE
Nat Commun; 2017 Oct; 8(1):1093. PubMed ID: 29061967
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.
Walton J; Blagih J; Ennis D; Leung E; Dowson S; Farquharson M; Tookman LA; Orange C; Athineos D; Mason S; Stevenson D; Blyth K; Strathdee D; Balkwill FR; Vousden K; Lockley M; McNeish IA
Cancer Res; 2016 Oct; 76(20):6118-6129. PubMed ID: 27530326
[TBL] [Abstract][Full Text] [Related]
8. TP53 loss initiates chromosomal instability in fallopian tube epithelial cells.
Bronder D; Tighe A; Wangsa D; Zong D; Meyer TJ; Wardenaar R; Minshall P; Hirsch D; Heselmeyer-Haddad K; Nelson L; Spierings D; McGrail JC; Cam M; Nussenzweig A; Foijer F; Ried T; Taylor SS
Dis Model Mech; 2021 Nov; 14(11):. PubMed ID: 34569598
[TBL] [Abstract][Full Text] [Related]
9. Epithelialization of mouse ovarian tumor cells originating in the fallopian tube stroma.
Hua Y; Choi PW; Trachtenberg AJ; Ng AC; Kuo WP; Ng SK; Dinulescu DM; Matzuk MM; Berkowitz RS; Ng SW
Oncotarget; 2016 Oct; 7(40):66077-66086. PubMed ID: 27602775
[TBL] [Abstract][Full Text] [Related]
10. Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.
Lõhmussaar K; Kopper O; Korving J; Begthel H; Vreuls CPH; van Es JH; Clevers H
Nat Commun; 2020 May; 11(1):2660. PubMed ID: 32461556
[TBL] [Abstract][Full Text] [Related]
11. Functional analysis of miR-34c as a putative tumor suppressor in high-grade serous ovarian cancer.
Yu Z; Kim J; He L; Creighton CJ; Gunaratne PH; Hawkins SM; Matzuk MM
Biol Reprod; 2014 Nov; 91(5):113. PubMed ID: 25273528
[TBL] [Abstract][Full Text] [Related]
12. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.
Sherman-Baust CA; Kuhn E; Valle BL; Shih IeM; Kurman RJ; Wang TL; Amano T; Ko MS; Miyoshi I; Araki Y; Lehrmann E; Zhang Y; Becker KG; Morin PJ
J Pathol; 2014 Jul; 233(3):228-37. PubMed ID: 24652535
[TBL] [Abstract][Full Text] [Related]
13. PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation.
Russo A; Czarnecki AA; Dean M; Modi DA; Lantvit DD; Hardy L; Baligod S; Davis DA; Wei JJ; Burdette JE
Oncogene; 2018 Apr; 37(15):1976-1990. PubMed ID: 29367766
[TBL] [Abstract][Full Text] [Related]
14. Whence High-Grade Serous Ovarian Cancer.
Kohn EC; Ivy SP
Am Soc Clin Oncol Educ Book; 2017; 37():443-448. PubMed ID: 28561656
[TBL] [Abstract][Full Text] [Related]
15. Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8.
Tudrej P; Olbryt M; Zembala-Nożyńska E; Kujawa KA; Cortez AJ; Fiszer-Kierzkowska A; Pigłowski W; Nikiel B; Głowala-Kosińska M; Bartkowska-Chrobok A; Smagur A; Fidyk W; Lisowska KM
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018258
[TBL] [Abstract][Full Text] [Related]
16. [The Fallopian tube odyssey: from the ovary to the tube. About high-grade serous ovarian carcinoma].
Chêne G; Dauplat J; Radosevic-Robin N; Cayre A; Penault-Llorca F
Bull Cancer; 2013; 100(7-8):757-64. PubMed ID: 23831931
[TBL] [Abstract][Full Text] [Related]
17. Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
McCool KW; Freeman ZT; Zhai Y; Wu R; Hu K; Liu CJ; Tomlins SA; Fearon ER; Magnuson B; Kuick R; Cho KR
Cancer Res; 2020 Feb; 80(4):877-889. PubMed ID: 31806642
[TBL] [Abstract][Full Text] [Related]
18. Two different, mutually exclusively distributed,
Sukhbaatar N; Bachmayr-Heyda A; Auer K; Aust S; Deycmar S; Horvat R; Pils D
Cold Spring Harb Mol Case Stud; 2017 Jul; 3(4):. PubMed ID: 28679689
[TBL] [Abstract][Full Text] [Related]
19. The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice.
Kim J; Coffey DM; Ma L; Matzuk MM
Endocrinology; 2015 Jun; 156(6):1975-81. PubMed ID: 25815421
[TBL] [Abstract][Full Text] [Related]
20. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]